

# Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/E08C69DE7DAEN.html>

Date: August 2019

Pages: 48

Price: US\$ 125.00 (Single User License)

ID: E08C69DE7DAEN

## Abstracts

Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Egalet Corp (Egalet), formerly Zyla Life Sciences, is a commercial-stage pharmaceutical company that commercializes innovative treatment options for inflammation and various types of pain. The company offers branded non-narcotic, nonsteroidal, and anti-inflammatory drugs and formulations including ketorolac tromethamine nasal spray, diclofenac, indomethacin, oxycodone HCl, USP, and meloxicam. Its acute and chronic pain products enable healthcare providers to address the issue of prescription abuse. The company harnesses its proprietary Guardian technology, a polymer matrix tablet technology, for advancing its pipeline products. Egalet is headquartered in Wayne, Pennsylvania, the US.

### Egalet Corp Key Recent Developments

Jun 19,2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors

Jun 12,2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer

May 16,2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences

Nov 19,2018: Egalet announces third quarter 2018 financial results

Aug 08,2018: Egalet reports second quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios

and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Egalet Corp - Key Facts  
Egalet Corp - Key Employees  
Egalet Corp - Key Employee Biographies  
Egalet Corp - Major Products and Services  
Egalet Corp - History  
Egalet Corp - Company Statement  
Egalet Corp - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Egalet Corp - Business Description  
Product Category: Arymo ER  
Performance  
Product Category: Oxaydo  
Performance  
Product Category: Sprix Nasal Spray  
Performance  
R&D Overview  
Egalet Corp - Corporate Strategy  
Egalet Corp - SWOT Analysis  
SWOT Analysis - Overview  
Egalet Corp - Strengths  
Egalet Corp - Weaknesses  
Egalet Corp - Opportunities  
Egalet Corp - Threats  
Egalet Corp - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart

Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019  
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019  
Egalet Corp, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Jun 19, 2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors  
Jun 12, 2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer  
May 16, 2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences  
Nov 19, 2018: Egalet announces third quarter 2018 financial results  
Aug 08, 2018: Egalet reports second quarter 2018 financial results  
Jun 07, 2018: Egalet Names John Varian Board Director  
May 08, 2018: Egalet Reports First Quarter 2018 Financial Results  
Mar 12, 2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results

## **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Egalet Corp, Key Facts  
Egalet Corp, Key Employees  
Egalet Corp, Key Employee Biographies  
Egalet Corp, Major Products and Services  
Egalet Corp, History  
Egalet Corp, Other Locations  
Egalet Corp, Subsidiaries  
Egalet Corp, Key Competitors  
Egalet Corp, Ratios based on current share price  
Egalet Corp, Annual Ratios  
Egalet Corp, Annual Ratios (Cont...1)  
Egalet Corp, Interim Ratios  
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019  
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019  
Egalet Corp, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Egalet Corp, Performance Chart (2014 - 2018)

Egalet Corp, Ratio Charts

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

### COMPANIES MENTIONED

Teva Pharmaceutical Industries, Ltd. - Portfolio of Generic Products – US

Pfizer Consumer Healthcare

Nektar Therapeutics

Mallinckrodt LLC

Endo Pharmaceuticals Inc

Actavis LLC



## I would like to order

Product name: Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/E08C69DE7DAEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E08C69DE7DAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970